Results 31 to 40 of about 1,889,174 (167)

Pharmacokinetics and Safety of Oxycodone/Naloxone Prolonged-Release Tablets in Chinese Patients with Chronic Pain

open access: yesDrug Design, Development and Therapy
Yongji He,1,2,* Ling Yang,1,2,* Qianqian Mou,1,2 Xiaotao Cao,1,2 Xiaohong Zhu,1,2 Ying Wang,1,2 Zhu Luo1,2 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Clinical Trial Center ...
He Y   +6 more
doaj  

Pharmacokinetics and Bioequivalence of Mycophenolate Sodium Enteric-Coated Tablets Under Fasting and Fed Conditions: A Single-Dose, Open-Label, Four-Period Replicated Crossover Study in Healthy Chinese Male Subjects

open access: yesDrug Design, Development and Therapy
Peiwen Zhang,1,* Mupeng Li,1,* Hao Jiang,2 Fangfang Liu,1 Qian Huang,1 Yangyun Han,1 Lianlian Fan1 1Phase 1 Clinical Trial Center, Deyang People′s Hospital, Deyang, Sichuan, People’s Republic of China; 2Zhejiang Meidishen Biomedical Co ...
Zhang P   +6 more
doaj  

Clinical trial evaluation: the EDOSURE clinical trial program [PDF]

open access: yesFuture Cardiology
EDOSURE is a trial program of the direct oral anticoagulant drug edoxaban, comprising ten randomized clinical trials of which eight are currently published. They evaluate the use of edoxaban in the treatment of nonvalvular atrial fibrillation and acute venous thromboembolism, including in special circumstances such as patients undergoing cardiac ...
Michael Griffin, Gregory YH Lip
openaire   +2 more sources

Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes

open access: yesTrials
Introduction ASCEND assessed the effects of randomisation to aspirin versus placebo and, separately omega-3 fatty acid (FA) supplementation versus placebo on vascular events in 15480 adults with diabetes using mail-based remote methods.
Vichithranie W. Madurasinghe   +4 more
doaj   +1 more source

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study

open access: yesDrug Design, Development and Therapy
Yue Fei,1 Zhihong Xie,2 Yuanyuan Luo,3 Xiaolan Yong,4 Na Li,1 Rong Huang,1 Xiaolin Du,4 Yijing Zhu,4 Dongmei Lan,3 Yang Qi,3 Gang Cheng,1 Quanren Wang,1 Kai Shen1 1Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, Shanghai, People’s ...
Fei Y   +12 more
doaj  

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]

open access: yesDrug Design, Development and Therapy
Fei Y, Xie Z, Luo Y, et al. Drug Des Devel Ther. 2025;19:3751–3761. Page 3760, first line, the text “Our current study had similar findings” should read “Our study observed an increase in the exposure to HRS ...
Fei Y   +12 more
doaj  

Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults

open access: yesNature Communications
Proteomics offers unique insights into human biology and drug development, but few studies have directly compared the utility of different proteomics platforms.
Baihan Wang   +25 more
doaj   +1 more source

On Clinical Trials

open access: yesOptometry and Vision Science, 2021
Lisa A, Jones Jordan, Michael D, Twa
openaire   +3 more sources

From Facial Measurement to Spatial Mapping: A Privacy-Preserving 3D Mesh Framework for Visualizing Skin Responses in Cosmetic Human Studies

open access: yesCosmetics
Conventional cosmetic human studies rely on pre–post mean comparisons, which have limitations in explaining where and how facial skin changes occur. This pilot single-arm study proposed a privacy-preserving three-dimensional (3D) facial mesh mapping ...
Youngrin Kwag   +6 more
doaj   +1 more source

Clinical trials on trial [PDF]

open access: yesEuropean Journal of Hospital Pharmacy, 2012
It has been 3 years since I wrote an editorial on the topic of uncertainty around new cancer treatments (issue 4 of volume 2009). Has this field progressed in 3 years? I think the answer is both yes and no. Yes because we now have a clearer picture of why cancer drugs can sometimes act differently (usually worse) in real life situations than they seem ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy